Refine
Year of publication
- 2015 (897) (remove)
Document Type
- Journal article (447)
- Doctoral Thesis (344)
- Complete part of issue (50)
- Book article / Book chapter (23)
- Review (7)
- Conference Proceeding (6)
- Working Paper (6)
- Book (5)
- Report (3)
- Jahresbericht (2)
Keywords
- Universität (47)
- University (46)
- Wuerzburg (46)
- Wurzburg (46)
- Würzburg (46)
- expression (19)
- ATLAS detector (18)
- proton-proton collision (13)
- cancer (11)
- in vitro (11)
Institute
- Theodor-Boveri-Institut für Biowissenschaften (98)
- Physikalisches Institut (87)
- Universität - Fakultätsübergreifend (46)
- Graduate School of Life Sciences (45)
- Neuphilologisches Institut - Moderne Fremdsprachen (36)
- Medizinische Klinik und Poliklinik I (34)
- Institut für Psychologie (32)
- Medizinische Klinik und Poliklinik II (32)
- Neurologische Klinik und Poliklinik (29)
- Klinik und Poliklinik für Psychiatrie, Psychosomatik und Psychotherapie (26)
Schriftenreihe
Sonstige beteiligte Institutionen
- ATLAS Collaboration (1)
- Adam Opel AG (1)
- Bayerische Museumsakademie (1)
- Bayerisches Zentrum für Angewandte Energieforschung e.V. (1)
- Bezirk Unterfranken (1)
- Brown University (1)
- CERN (1)
- Center for Nanosystems Chemistry (CNC), Universität Würzburg, Am Hubland, 97074 Würzburg, Germany (1)
- Deutscher Akademischer Austauschdienst (DAAD) (1)
- Deutsches Zentrum für Luft- und Raumfahrt (DLR), Institut für Raumfahrtsysteme (1)
ResearcherID
- B-1911-2015 (1)
- C-2593-2016 (1)
- D-1221-2009 (1)
- N-2030-2015 (1)
- N-3741-2015 (1)
Microbial species (bacteria and archaea) in the gut are important for human health in various ways. Not only does the species composition vary considerably within the human population, but each individual also appears to have its own strains of a given species. While it is known from studies of bacterial pan-genomes, that genetic variation between strains can differ considerably, such as in Escherichia coli, the extent of genetic variation of strains for abundant gut species has not been surveyed in a natural habitat. This is mainly due to the fact that most of these species cannot be cultured in the laboratory. Genetic variation can range from microscale genomic rearrangements such as small nucleotide polymorphism (SNP) to macroscale large genomic rearrangements like structural variations. Metagenomics offers an alternative solution to study genetic variation in prokaryotes, as it involves DNA sequencing of the whole community directly from the environment. However, most metagenomic studies to date only focus on variation in gene abundance and hence are not able to characterize genetic variation (in terms of presence or absence of SNPs and genes) of gut microbial strains of individuals.
The aim of my doctorate studies was therefore to study the extent of genetic variation in the genomic sequence of gut prokaryotic species and its phenotypic effects based on: (1) the impact of SNP variation in gut bacterial species, by focusing on genes under selective pressure and (2) the gene content variation (as a proxy for structural variation) and their effect on microbial species and the phenotypic traits of their human host.
In the first part of my doctorate studies, I was involved in a project in which we created a catalogue of 10.3 million SNPs in gut prokaryotic species, based on metagenomes. I used this to perform the first SNP-based comparative study of prokaryotic species evolution in a natural habitat. Here, I found that strains of gut microbial species in different individuals evolve at more similar rates than the strains within an individual. In addition, I found that gene evolution can be uncoupled from the evolution of its originating species, and that this could be related to selective pressure such as diet, exemplified by galactokinase gene (galK). Despite the individuality (i.e. uniqueness of each individual within the studied metagenomic dataset) in the SNP profile of the gut microbiota that we found, for most cases it is not possible to link SNPs with phenotypic differences. For this reason I also used gene content as a proxy to study structural variation in metagenomes.
In the second part of my doctorate studies, I developed a methodology to characterize the variability of gene content in gut bacterial species, using metagenomes. My approach is based on gene deletions, and was applied to abundant species (demonstrated using a set of 11 species). The method is sufficiently robust as it captures a similar range of gene content variability as has been detected in completely sequenced genomes. Using this procedure I found individuals differ by an average of 13% in their gene content of gut bacterial strains within the same species. Interestingly no two individuals shared the same gene content across bacterial species. However, this variation corresponds to a lower limit, as it is only accounts for gene deletion and not insertions. This large variation in the gene content of gut strain was found to affect important functions, such as polysaccharide utilization loci (PULs) and capsular polysaccharide synthesis (CPS), which are related with digestion of dietary fibers.
In summary, I have shown that metagenomics based approaches can be robust in characterizing genetic variation in gut bacterial species. I also illustrated, using examples both for SNPs and gene content (galK, PULs and CPS), that this genetic variation can be used to predict the phenotypic characteristics of the microbial species, as well as predicting the phenotype of their human host (for example, their capacity to digest different food components). Overall, the results of my thesis highlight the importance of characterizing the strains in the gut microbiome analogous to the emerging variability and importance of human genomics.
Jahresbericht 2013
(2015)
Protein kinases as targets for the development of novel drugs against alveolar echinococcosis
(2015)
The metacestode larval stage of the fox tapeworm Echinococcus multilocularis is the causative agent of alveolar echinococcosis (AE), one of the most lethal zoonosis of the northern hemisphere. The development of metacestode vesicles by asexual multiplication and the almost unrestricted infiltrative growth within the host organs is ensured from a population of undifferentiated, proliferative cells, so-called germinative cells. AE treatment options include surgery, if possible, as well as Benzimidazole-based chemotherapy (BZ). Given that the cellular targets of BZs, the -tubulins, are highly conserved between cestodes and humans, the chemotherapy is associated with considerable side-effects. Therefore, BZ can only be applied in parasitostatic doses and has to be given lifelong. Furthermore, the current anti-AE chemotherapy is ineffective in eliminating the germinative cell population of the parasite, which leads to remission of parasite growth as soon as therapy is discontinued.
This work focuses on protein kinases involved in the proliferation and development of the parasite with the intention of developing novel anti-AE therapies. Polo-like kinases (Plks) are important regulators of the eukaryotic cell cycle and are involved in the regulation and formation of the mitotic spindles during the M-phase of the cell cycle. Plks have already been shown to be associated with deregulated cellular growth in human cancers and have been investigated as novel drug targets in the flatworm parasite Schistosoma mansoni. In the first part of this work, the characterisation of a novel and druggable parasite enzyme, EmPlk1, which is homologous to the polo-like kinase 1 (Plk1) of humans and S. mansoni (SmPlk1), is presented. Through in situ hybridisation, it could be demonstrated that emplk1 is specifically expressed in the Echinococcus germinative cells. Upon heterologous expression in the Xenopus oocyte system, EmPlk1 induced germinal vesicle breakdown, thus indicating that it is an active kinase. Furthermore, BI 2536, a compound originally designed to inhibit the human ortholog of EmPlk1, inhibited the EmPlk1 activity at a concentration of 25 nM. In vitro treatment of parasite vesicles with similar concentrations of BI 2536 led to the elimination of the germinative cells from Echinococcus larvae, thus preventing the growth and further development of the parasite. In in vitro cultivation systems for parasite primary cells, BI 2536 effectively inhibited the formation of new metacestode vesicles from germinative cells. Thus, BI 2536 has profound anti-parasitic activities in vitro at concentrations well within the range of plasma levels measured after the administration of safe dosages to patients (50 nM after 24 h). This implies that EmPlk1 is a promising new drug target for the development of novel anti-AE drugs that would specifically affect the parasite’s stem cell population, namely the only parasite cells capable of proliferation. In addition to the chemotherapeutic aspects of this work, the inhibitor BI 2536 could be further used to study the function of stem cells in this model organism, utilising a method of injection of parasite stem cells into metacestode vesicles, for instance, as has been developed in this work.
In the second part of this work, a novel receptor tyrosine kinase, the Venus flytrap kinase receptor (EmVKR) of E. multilocularis has been characterised. Members of this class of single-pass transmembrane receptors have recently been discovered in the related trematode S. mansoni and are associated with the growth and differentiation of sporocyst germinal cells and ovocytes. The ortholog receptor in EmVKR is characterised by an unusual domain composition of an extracellular Venus flytrap module (VFT), which shows significant similarity to GABA receptors, such as the GABAB receptor (γ-amino butyric acid type B) and is linked through a single transmembrane domain to an intracellular tyrosine kinase domain with similarities to the kinase domains of human insulin receptors. Based upon the size (5112bp) of emvkr and nucleotide sequence specificities, efforts have been made to isolate the gene from cell culture samples to study the ligand for the activation of this receptor type in Xenopus oocytes. To date, this type of receptor has only been described in invertebrates, thus making it an attractive target for drug screening. In a first trial, the ATP competitive inhibitor AG 1024 was tested in our in vitro cell culture.
In conclusion, the EmVKR represents a novel receptor tyrosine kinase in E. multilocularis. Further efforts have to be made to identify the activating ligand of the receptor and its cellular function, which might strengthen the case for EmVKR as a potential drug target. The successful depletion of stem cells in the metacestode vesicle by the Plk1 inhibitor BI 2536 gives rise to optimising the chemical component for EmPlk1 as a new potential drug target. Furthermore, this inhibitor opens a new cell culture technique with high potential to study the cellular behaviour and influencing factors of stem cells in vitro.
Weltweit zählt die Tuberkulose zu den tödlichsten und am weitesten verbreiteten Infektionskrankheiten. Missstände in der ohnehin komplexen Therapie einerseits und fehlende Entwicklung neuartiger adäquater Wirkstoffe andererseits, führten zur Entstehung von multi- und sogar total-resistenten Keimen. Der Haupterreger ist das Mycobacterium tuberculosis. Charakteristisch für Mykobakterien ist eine dicke und undurchlässige wachsartige Zellwand mit einem großen Anteil an bestimmten Fettsäuren. Die mykobakterielle Biosynthese dieser Fettsäuren unterscheidet sich stark von eukaryotischen Zellen. Die selektive Beeinflussung dieses Systems führt zu nicht überlebensfähigen Mykobakterien und stellt somit ein idealer Angriffspunkt für Arzneistoffe dar.
Die vorliegende Arbeit befasst sich mit der Entwicklung neuartiger direkter Hemmstoffe von InhA, einem für den Zellwandaufbau des Mycobacterium tuberculosis essenziellem Enzym.
Es wurden zwei photometrische gekoppelt-enzymatische Assay-Systeme im 96-Well-Format entwickelt, die sich das Absorptions- bzw. Fluoreszenzverhalten des Coenzyms NADH zu Nutze machen.
Das hierzu benötigte Enzym InhA wurde überexprimiert und aufgereinigt. Mehrere Synthesemethoden für das im Testverfahren verwendete Substrat 2-trans-Octenoyl-CoA (2toCoA) wurden etabliert.
Die etablierten Assay-Systeme wurden mit Hilfe von Positivkontrollen validiert. Grundlegende Experimente zur Errichtung einer substratunabhängigen orthogonalen Methode mittels MST wurden getätigt.
Basierend auf den Ergebnissen eines in Vorarbeiten durchgeführten virtuellen Screenings wurden erste potenzielle Inhibitoren kommerziell erworben und getestet. Nachfolgend wurde mit der Synthese von Derivaten begonnen, welche auf iterativem Wege optimiert wurden (Testung – Docking – Synthese neuer Derivate). Hierdurch wurde eine umfassende Substanzbibliothek bestehend aus insgesamt 254 Verbindungen aufgebaut. Diese setzte sich aus unterschiedlich substituierten Thiazolidin-2,4-dionen- und Thiazolin-2-on-Derivaten, Derivaten der ähnlich strukturierten Fünfring-Heterozyklen Rhodanine, Thiohydantoine und Hydantoine und weiteren Strukturklassen bestehend aus Biphenylether-, Pyrrolidoncarboxamid-, Pyridon- und Sulfonamid-Derivaten zusammen. Die Verbindungen wurden entweder selbst synthetisiert, kommerziell erworben oder von Kooperationspartnern bezogen. Neben der Etablierung zuverlässiger und effizienter Syntheserouten stand hierbei ebenso die strukturelle Aufklärung der stereochemischen Verhältnisse der Produkte im Mittelpunkt.
Die Verbindungen der aufgebauten Substanzbibliothek wurden mit dem etablierten InhA-Testsystem auf ihre inhibitorischen Eigenschaften gegenüber InhA untersucht. Soweit möglich wurden Struktur-Aktivitätsbeziehungen abgeleitet. Insbesondere einige disubstituierte Thiazolidindione zeigten eine schwache Hemmung von bis zu 25 %. Die zur Aufklärung des Inhibitionsmechanismus durchgeführten Experimente deuten auf eine unkompetitive Hemmung hin. Bei den direkten Testungen an Mykobakterien konnten die inhibitorischen Eigenschaften hingegen nicht bestätigt werden.
Weiterhin wurden Testungen an Cystein- und Serin-Proteasen von Erregern anderer Infektionskrankheiten durchgeführt. Das Thiazolinon SV102 wurde hierbei als nicht-kompetitiver Hemmstoff von Cathepsin B mit einem Ki-Wert von 1.3 µM identifiziert. Die Synthese und Testung weiterer Thiazolin-2-on-Derivate sowie Cokristallisationsversuche mit Cathepsin B sind somit in Betracht zu ziehen. Die getesteten Thiazolidindion-Derivate der Substanzbibliothek zeigten hierbei mittelstarke bis gute Hemmeigenschaften, die ebenfalls an den Erregern beobachtbar waren. Relativiert werden diese vielversprechenden Ergebnisse allerdings durch eine ebenfalls zu beobachtende Zytotoxizität. Weiterhin konnte eine antibakterielle Wirkung der untersuchten Verbindungen in zellulären Assay-Systemen nicht gezeigt werden.
Abschließend wurde die Eignung der Thiazolidindione und verwandter Fünfringheterozyklen als Leitstruktur für potenzielle InhA-Inhibitoren, aber auch die Eignung dieser Verbindungsklasse als potenzielle Leitstruktur per se diskutiert.